Hepatitis B vaccination. Three decision strategies for the individual. NLM AIDSLINE Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Hepatitis B vaccination. Three decision strategies for the individual.

Am J Med. 1984 Dec;77(6):1023-6. Unique Identifier : AIDSLINE MED/85069521
Littenberg B; Ransohoff DF

Abstract: Three strategies regarding hepatitis B virus vaccination were compared by decision analysis: no vaccination, immediate vaccination, and vaccination after two years. The potential advantage of waiting two years is to learn whether serious side effects of the vaccine will become evident. For example, it was found that immediate hepatitis B vaccination of 100,000 surgical house officers with a 5 percent annual attack rate for five years would, compared with no vaccination, prevent 4,092 cases of icteric hepatitis, 335 cases of chronic active hepatitis, and 15 deaths from fulminant hepatitis. For a strategy of waiting two years, the number of cases prevented would decrease by about 40 percent. Persons in groups with an annual attack rate lower than 5 percent appear to benefit from vaccination. The known health risks of hepatitis B virus vaccination are low, and the hypothesized risks would have to be frequent to justify delay in vaccination. From an individual perspective, even persons at low risk of hepatitis B virus infection should seriously consider immediate vaccination.
Keywords: Acquired Immunodeficiency Syndrome/ETIOLOGY Comparative Study Decision Making Drug Evaluation Hepatitis B/MORTALITY/*PREVENTION & CONTROL Human Risk Support, Non-U.S. Gov't *Vaccination/ADVERSE EFFECTS Viral Hepatitis Vaccines/ADMINISTRATION & DOSAGE/*ADVERSE EFFECTS JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/etiologycomparativestudydecisionmakingdrugevaluationhepatitisb/mortality/KWDprevention&controlhumanrisksupport,non-uKWDsKWDgov'tKWDvaccination/adverseeffectsviralhepatitisvaccines/administration&dosage/KWDadverseeffectsjournalarticle
850330
M8530077

Copyright © 1985 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1985. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .